NCT06706609Not yet recruiting
Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population
Source: ClinicalTrials.gov · Last updated 26 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to classify adult-onset diabetes patients into distinct data-driven clusters, such as severe insulin-deficient, severe insulin-resistant, mild obesity-related, and mild age-related diabetes, based on clinical and biochemical characteristics. Using a cross-sectional design, data will be collected from individuals attending outpatient diabetes clinics at tertiary care hospitals in Pakistan. The study will analyze the distribution of metabolic and demographic characteristics within each cluster and assess subgroup-specific risks for diabetic complications. Additionally, the relationship between clustering variables and the risk of complications will be evaluated to enhance the understanding of diabetes heterogeneity and its impact on patient outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 394 (estimated)
- First submitted
- 22 Nov 2024
- Start date
- 1 Feb 2025
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- Getz Pharma
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT06706609
What you commit to
- Study type: Observational
- Planned participants: 394
- From 1 Feb 2025 to the primary completion date, 1 Aug 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other medical comorbidities (not a complication of diabetes), such as malignancies.
Other
- Pregnancy
Who the study is looking for
- Patients of both genders whose age of disease onset was older than 16 years
- Patients newly diagnosed with or previously diagnosed with T2D
- Able and willing to provide written informed consent and to comply with the study
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.